ahuebner@guardanthealth.com
September 16, 2024
An Open Letter from AmirAli Talasaz, co-CEO of Guardant Health
To Our Patients, Healthcare Providers, Partners, and Employees, At Guardant Health, we are committed to bringing innovative and accurate cancer diagnostic tools
August 5, 2024
FDA Approves Blood Test for Colon Cancer Detection
June 11, 2024
FDA Advisory Committee Strongly Recommends Approval For Guardant Health Blood Test For Colorectal Cancer
Panel recommends approval of Shield as primary non-invasive screening option in adults aged 45 and older at average risk for the disease
May 21, 2024
Let’s Enter a New Era of Options for Colorectal Cancer Screening
Colorectal cancer is the second-leading cause of cancer death in the United States. Rates are rising in younger – and middle-aged individuals.
